The acceptability of opioid substitution treatment, Espranor.
Research type
Research Study
Full title
The acceptability of a new opioid substitution treatment (OST) product, Espranor (buprenorphine oral lyophilisate) in people receiving treatment for opiate dependence.
IRAS ID
234279
Contact name
Harry Wallace
Contact email
Sponsor organisation
CGL
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
change, grow, live (CGL) are charity offering services to empower people to improve their health and wellbeing and take control of the direction of their lives.
Our areas of expertise include:
• Substance misuse
• Children and young people’s services
• Family services
• Accommodation & homelessness
• Clinical services
• Criminal justiceCGL are offering a new formulation of buprenorphine, Espranor (buprenorphine oral lyophilisate) to service users in five CGL treatment services across England. This study will observe the uptake and acceptability of Espranor as an alternative treatment formulation of buprenorphine amongst service users trying the new formulation, over a six month period.
Espranor is an innovative formulation of buprenorphine as an oral wafer that offers instant disintegration and rapid dissolution, providing potential benefits to both staff and service users in reducing the time taken to dispense and absorb the medication. Whilst new to buprenorphine, the formulation is a tried and tested technology used in a range of existing drugs on the market to enable delivery, including: Olanzapine (schizophrenia), Selegiline (Parkinson’s disease) and Loperamide (diarrhoea). CGL is keen to assess the potential benefits of new formulations in improving patient experience and the journey towards recovery.
The study will: assess the acceptability of Espranor in people receiving treatment for opiate dependence; identify service user characteristics of those who try Espranor, explore service user compliance with prescribing regime and treatment preference at the end of the six-month period.
It will also assess pharmacist satisfaction in dispensing the new formulation and record any reductions in time for supervised consumption that the rapid dissolution formulation offers.
Primary measures: Service user acceptability of the product, service user characteristics of those who take up Espranor, overall compliance to prescribing regime and treatment preference post study period.
Secondary measures: Pharmacist satisfaction with the product, reduction in time taken over supervised consumption
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
17/EM/0410
Date of REC Opinion
27 Nov 2017
REC opinion
Further Information Favourable Opinion